How Do Gut Microbes Reroute Nanomedicines? Bile Acid Signaling Shapes Liver Clearance and Anticancer Efficacy

After nanomedicines enter the bloodstream, only a limited proportion often reaches tumors. Many particles are sequestered by the liver before arriving at their destination. A study published in *Nature Materials* indicates that this clearance checkpoint depends not only on nanoparticle size, material, or surface design, but may also be influenced by the metabolic environment created by gut microorganisms.

The research team used germ-free mice, antibiotic perturbation, fecal microbiota transplantation, and multi-omics analyses to investigate the relationship between the gut microbiota and nanomedicine distribution. The results showed that after metronidazole altered the gut microbial ecosystem, the liver’s uptake of nanoparticles decreased, allowing more drug to accumulate in tumors across multiple nanoformulations and mouse tumor models.

At the center of the mechanism are Kupffer cells, the liver-resident macrophages responsible for engulfing foreign substances. Single-cell RNA sequencing showed that after microbial perturbation, the composition of these cells shifted from a more actively phagocytic state toward a relatively quiescent state with lower uptake capacity, thereby reducing the sequestration of nanoparticles in the liver.

Metabolomic analysis pointed to bile acids as the signal between the gut and the liver. The microbiota changes caused by metronidazole were accompanied by a decline in bile acid availability; experiments also showed that bile acids derived from the metabolic activity of gut bacteria can promote phagocytosis by Kupffer cells. In other words, gut microbes, bile acids, and liver macrophages form a pathway that collectively determines how strongly the body clears nanomedicines.

This state could also be transferred to other mice through fecal microbiota transplantation, supporting a causal role for the microbiota itself rather than its being merely a bystander indicator of treatment response. In tumor models, lower liver clearance not only increased the extent to which nanomedicines entered tumors, but also enhanced the therapeutic effect of nanochemotherapy, suggesting that the microbiome may be a biological variable that needs to be controlled or used for stratification in preclinical drug-delivery research.

However, the existing evidence comes mainly from mice and does not yet support the conclusion that patients who use antibiotics or receive microbiota transplantation would experience improved nanomedicine efficacy. Antibiotics may broadly alter the microbiome and may also introduce risks involving infection, antimicrobial resistance, and interactions with other treatments; whether different nanoformulations and the human microbiota follow the same mechanism still requires validation using clinical samples and prospective studies. For now, these findings are closer to a new mechanistic map of drug delivery than to a cancer treatment strategy that can be adopted directly.